Pub Date : 2024-10-10DOI: 10.1007/s10047-024-01476-6
Weronika Koziak, Stanisław Dudek, Zbigniew Putowski, Filippo Sanfilippo, Mateusz Zawadka
A thyroid storm is the most extreme and life-threatening presentation of thyrotoxicosis. Thyroidectomy can be used for definitive treatment. It should be performed after euthyroidism is accomplished. The use of therapeutic plasma exchange (TPE) is a last resort option in cases where standard pharmacological therapy proves to be ineffective. Due to its rare prevalence, there are limited data evaluating the usefulness and efficacy of TPE as a bridging therapy to thyroidectomy. The absence of relevant literature prompted us to conduct a scoping review. The following bibliographic databases were searched for articles dated 30 November 2023: Medline, EMBASE, Web of Science and Google Scholar. The search identified 1047 records, of which 42 articles were accepted with a total of 234 patients. The dominant indications for TPE were side effects due to conventional treatment. The mean fT4 level decreased 51.9% of baseline after TPE, while the mean fT3 level decreased 66.6% of baseline. The main side effects observed with FFP were allergic reactions, while the use of an albumin solution was associated with perioperative bleeding. Based on the limited data available in the literature, we recognize plasmapheresis as an effective treatment option for reducing thyroid hormone levels prior to thyroidectomy in patients with thyrotoxicosis. Available data suggest that it might be reasonable to limit the number of sessions in favor of an earlier surgical intervention. To reduce the risk of bleeding, FFP may be a better option as a replacement fluid, especially in the session prior to thyroidectomy.
{"title":"Exploring the role of plasmapheresis prior to thyroidectomy in managing thyrotoxicosis: a comprehensive scoping review.","authors":"Weronika Koziak, Stanisław Dudek, Zbigniew Putowski, Filippo Sanfilippo, Mateusz Zawadka","doi":"10.1007/s10047-024-01476-6","DOIUrl":"https://doi.org/10.1007/s10047-024-01476-6","url":null,"abstract":"<p><p>A thyroid storm is the most extreme and life-threatening presentation of thyrotoxicosis. Thyroidectomy can be used for definitive treatment. It should be performed after euthyroidism is accomplished. The use of therapeutic plasma exchange (TPE) is a last resort option in cases where standard pharmacological therapy proves to be ineffective. Due to its rare prevalence, there are limited data evaluating the usefulness and efficacy of TPE as a bridging therapy to thyroidectomy. The absence of relevant literature prompted us to conduct a scoping review. The following bibliographic databases were searched for articles dated 30 November 2023: Medline, EMBASE, Web of Science and Google Scholar. The search identified 1047 records, of which 42 articles were accepted with a total of 234 patients. The dominant indications for TPE were side effects due to conventional treatment. The mean fT4 level decreased 51.9% of baseline after TPE, while the mean fT3 level decreased 66.6% of baseline. The main side effects observed with FFP were allergic reactions, while the use of an albumin solution was associated with perioperative bleeding. Based on the limited data available in the literature, we recognize plasmapheresis as an effective treatment option for reducing thyroid hormone levels prior to thyroidectomy in patients with thyrotoxicosis. Available data suggest that it might be reasonable to limit the number of sessions in favor of an earlier surgical intervention. To reduce the risk of bleeding, FFP may be a better option as a replacement fluid, especially in the session prior to thyroidectomy.</p>","PeriodicalId":15177,"journal":{"name":"Journal of Artificial Organs","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142400375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
We established a compact machine perfusion system for whole blood perfusion of rat liver by making use of oxygenation filters as an artificial lung. Livers removed from rats were divided into Krebs-Henseleit (control), 50% blood (hemoglobin: 7 g/dL), and whole blood (hemoglobin: 14 g/dL) groups, then perfused (total perfusate volume: 25 ml) with a small oxygenation filter at 37 °C for 120 min. Blood or perfusate was collected over time, and blood gas and blood cell were measured. In addition, bile volume and portal venous pressure measurements were taken. In all groups, the partial pressure of oxygen was controlled to approximately 400 mmHg. Flow rates were maintained at approximately about 20-30 ml/min according to liver size. Portal venous pressure was normal in the 50% blood and whole blood groups, while lower than the reference value in the Krebs-Henseleit group. Twice as much bile was produced in the 50% blood and whole blood groups relative with the Krebs-Henseleit group. We observed no differences in hemoglobin and red blood cell levels. Lactate levels were normal in the 50% blood and whole blood groups, but were elevated in the Krebs-Henseleit group. Our compact perfusion system using oxygenation filters was able to maintain rat liver function by perfusing a small amount of extracorporeal blood. This system is simple and stable, and may contribute to the future development of machine perfusion systems.
{"title":"A compact machine perfusion device for whole blood perfusion in isolated rat liver.","authors":"Yuki Tamaki, Naoyuki Hatayama, Yutaka Fujii, Munekazu Naito","doi":"10.1007/s10047-024-01474-8","DOIUrl":"https://doi.org/10.1007/s10047-024-01474-8","url":null,"abstract":"<p><p>We established a compact machine perfusion system for whole blood perfusion of rat liver by making use of oxygenation filters as an artificial lung. Livers removed from rats were divided into Krebs-Henseleit (control), 50% blood (hemoglobin: 7 g/dL), and whole blood (hemoglobin: 14 g/dL) groups, then perfused (total perfusate volume: 25 ml) with a small oxygenation filter at 37 °C for 120 min. Blood or perfusate was collected over time, and blood gas and blood cell were measured. In addition, bile volume and portal venous pressure measurements were taken. In all groups, the partial pressure of oxygen was controlled to approximately 400 mmHg. Flow rates were maintained at approximately about 20-30 ml/min according to liver size. Portal venous pressure was normal in the 50% blood and whole blood groups, while lower than the reference value in the Krebs-Henseleit group. Twice as much bile was produced in the 50% blood and whole blood groups relative with the Krebs-Henseleit group. We observed no differences in hemoglobin and red blood cell levels. Lactate levels were normal in the 50% blood and whole blood groups, but were elevated in the Krebs-Henseleit group. Our compact perfusion system using oxygenation filters was able to maintain rat liver function by perfusing a small amount of extracorporeal blood. This system is simple and stable, and may contribute to the future development of machine perfusion systems.</p>","PeriodicalId":15177,"journal":{"name":"Journal of Artificial Organs","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142371879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-27DOI: 10.1007/s10047-024-01470-y
Vyacheslav Shulunov
Improvements in the roll porous scaffold (RPS) 3D bioproduction technology will increase print density of 10-15 µm cells by ~ 20% up to ~ 1.5 × 108 cells/mL and purity of organoid formation by > 17%. The use of 360 and 1200 dpi inkjet printheads immediately enables biomanufacturing with 10-30 µm cells in a single organoid with performance > 1.8 L/h for 15 µm layer thickness. The spongy bioresorbable ribbon for RPS technology is designed to solve the problems of precise placement, leakage and increasing in the number of instantly useable cell types and superior to all currently dominant 3D bioprinting methods in speed, volume, and print density without the use of expensive equipment and components. The potential of RPS for parallel testing of new substances studied was not on animals, but using generated 3D biomodels "organ on a chip". Solid organoids are more suitable for personalized medicine with simultaneous checking of several treatment methods and drugs, targeted therapy for a specific patient in vitro using the 3D composition of his personal cells, and selection of the most effective ones with the least toxicity. Overcoming the shortage of organs for implantation and personal hormone replacement therapy for everyone was achieved using printed endocrine glands based on their DNA.
{"title":"Advanced roll porous scaffold 3D bioprinting technology.","authors":"Vyacheslav Shulunov","doi":"10.1007/s10047-024-01470-y","DOIUrl":"https://doi.org/10.1007/s10047-024-01470-y","url":null,"abstract":"<p><p>Improvements in the roll porous scaffold (RPS) 3D bioproduction technology will increase print density of 10-15 µm cells by ~ 20% up to ~ 1.5 × 10<sup>8</sup> cells/mL and purity of organoid formation by > 17%. The use of 360 and 1200 dpi inkjet printheads immediately enables biomanufacturing with 10-30 µm cells in a single organoid with performance > 1.8 L/h for 15 µm layer thickness. The spongy bioresorbable ribbon for RPS technology is designed to solve the problems of precise placement, leakage and increasing in the number of instantly useable cell types and superior to all currently dominant 3D bioprinting methods in speed, volume, and print density without the use of expensive equipment and components. The potential of RPS for parallel testing of new substances studied was not on animals, but using generated 3D biomodels \"organ on a chip\". Solid organoids are more suitable for personalized medicine with simultaneous checking of several treatment methods and drugs, targeted therapy for a specific patient in vitro using the 3D composition of his personal cells, and selection of the most effective ones with the least toxicity. Overcoming the shortage of organs for implantation and personal hormone replacement therapy for everyone was achieved using printed endocrine glands based on their DNA.</p>","PeriodicalId":15177,"journal":{"name":"Journal of Artificial Organs","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142347289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The spleen size may be associated with mortality and morbidity in patients with heart failure, whereas its clinical implication in patients with cardiogenic shock receiving Impella-incorporated temporary mechanical circulatory support (MCS) remains unknown. Patients who received Impella-incorporated temporary MCS in our institute between March 2018 and August 2023 were eligible. The splenic volume index (SVI) was retrospectively calculated in all participants by measuring spleen size on the computed tomography obtained at the time of Impella placement. The impact of baseline SVI/central venous pressure (CVP) ratio on the 30-day mortality after Impella placement was evaluated. A total of 74 patients (70 years old, 62% men) were included. Median baseline SVI was 71.6 (50.3, 92.1) mL/m2. A lower SVI was associated with more decreased cardiac output and a higher SVI was associated with more elevated CVP (p < 0.05 for both). A lower SVI/CVP ratio was associated with higher 30-day mortality with an adjusted hazard ratio of 3.734 (95% confidence interval 1.397–9.981, p = 0.009). A baseline lower SVI/CVP ratio was associated with short-term mortality in patients receiving Impella-incorporated temporary MCS.
脾脏大小可能与心力衰竭患者的死亡率和发病率有关,但其对接受Impella融入式临时机械循环支持(MCS)的心源性休克患者的临床影响尚不清楚。2018年3月至2023年8月期间在我院接受Impella融入式临时机械循环支持的患者符合条件。所有参与者的脾脏体积指数(SVI)都是通过测量置入Impella时获得的计算机断层扫描上的脾脏大小进行回顾性计算的。评估了基线SVI/中心静脉压(CVP)比值对Impella置管后30天死亡率的影响。共纳入了 74 名患者(70 岁,62% 为男性)。基线 SVI 中位数为 71.6 (50.3, 92.1) mL/m2。较低的 SVI 与较低的心输出量相关,而较高的 SVI 与较高的 CVP 相关(两者的 p 均为 0.05)。较低的 SVI/CVP 比值与较高的 30 天死亡率相关,调整后的危险比为 3.734(95% 置信区间为 1.397-9.981,p = 0.009)。基线较低的 SVI/CVP 比率与接受 Impella 植入式临时 MCS 患者的短期死亡率有关。
{"title":"Impact of the spleen size on short-term prognosis in patients with cardiogenic shock receiving Impella-incorporated temporary mechanical circulatory support","authors":"Makiko Nakamura, Teruhiko Imamura, Hayato Fujioka, Masaki Nakagaito, Hiroshi Ueno, Koichiro Kinugawa","doi":"10.1007/s10047-024-01472-w","DOIUrl":"https://doi.org/10.1007/s10047-024-01472-w","url":null,"abstract":"<p>The spleen size may be associated with mortality and morbidity in patients with heart failure, whereas its clinical implication in patients with cardiogenic shock receiving Impella-incorporated temporary mechanical circulatory support (MCS) remains unknown. Patients who received Impella-incorporated temporary MCS in our institute between March 2018 and August 2023 were eligible. The splenic volume index (SVI) was retrospectively calculated in all participants by measuring spleen size on the computed tomography obtained at the time of Impella placement. The impact of baseline SVI/central venous pressure (CVP) ratio on the 30-day mortality after Impella placement was evaluated. A total of 74 patients (70 years old, 62% men) were included. Median baseline SVI was 71.6 (50.3, 92.1) mL/m<sup>2</sup>. A lower SVI was associated with more decreased cardiac output and a higher SVI was associated with more elevated CVP (<i>p</i> < 0.05 for both). A lower SVI/CVP ratio was associated with higher 30-day mortality with an adjusted hazard ratio of 3.734 (95% confidence interval 1.397–9.981, <i>p</i> = 0.009). A baseline lower SVI/CVP ratio was associated with short-term mortality in patients receiving Impella-incorporated temporary MCS.</p>","PeriodicalId":15177,"journal":{"name":"Journal of Artificial Organs","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2024-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142259651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A portable axial-flow polymer bridge pump with hydrodynamic bearings has been developed for bridge-to-bridge use. The pump is inexpensive to manufacture and disposable. It weighs 185 g and was verified to have a lifetime of 3 months with silent operation. For partial circulatory assist at a flow rate of 2 L/min, the clinical limit of hemolysis was verified for a rotational speed below 9000 rpm, at which a pressure of 100 mmHg was generated. In an anti-thrombogenic test, the pump stably operated for 6 h without thrombus formation.
{"title":"Axial-flow polymer bridge pump with hydrodynamic bearings","authors":"Takashi Yamane, Eiru Akao, Toshinori Kashiwazaki, Yojiro Koda, Hiroshi Tanaka","doi":"10.1007/s10047-024-01465-9","DOIUrl":"https://doi.org/10.1007/s10047-024-01465-9","url":null,"abstract":"<p>A portable axial-flow polymer bridge pump with hydrodynamic bearings has been developed for bridge-to-bridge use. The pump is inexpensive to manufacture and disposable. It weighs 185 g and was verified to have a lifetime of 3 months with silent operation. For partial circulatory assist at a flow rate of 2 L/min, the clinical limit of hemolysis was verified for a rotational speed below 9000 rpm, at which a pressure of 100 mmHg was generated. In an anti-thrombogenic test, the pump stably operated for 6 h without thrombus formation.</p>","PeriodicalId":15177,"journal":{"name":"Journal of Artificial Organs","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2024-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142259652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The utilization of temporary mechanical circulatory support (MCS) in the management of cardiogenic shock is experiencing a notable surge. Acute myocardial infarction remains the predominant etiology of cardiogenic shock, followed by heart failure. Recent findings from the DanGer Shock trial indicate that the percutaneous micro-axial flow pump support, in conjunction with standard care, significantly reduced 6-month mortality in patients with acute myocardial infarction-related cardiogenic shock compared to those receiving standard care alone. However, real-world registry data reveal that the 30-day mortality among patients with acute myocardial infarction-related cardiogenic shock, who received concomitant veno-arterial extracorporeal membrane oxygenation support along with micro-axial flow pump, remain suboptimal. The persistent challenge in the field is how to incorporate, escalate, and de-escalate these temporary MCS to further improve clinical outcomes in such clinical scenarios. This review aims to elucidate the current practices surrounding the escalation and de-escalation of temporary MCS in real-world clinical settings and proposes considerations for future advancements in this critical area.
{"title":"Contemporary optimal therapeutic strategy with escalation/de-escalation of temporary mechanical circulatory support in patients with cardiogenic shock and advanced heart failure in Japan.","authors":"Makiko Nakamura, Teruhiko Imamura, Kinugawa Koichiro","doi":"10.1007/s10047-024-01471-x","DOIUrl":"https://doi.org/10.1007/s10047-024-01471-x","url":null,"abstract":"<p><p>The utilization of temporary mechanical circulatory support (MCS) in the management of cardiogenic shock is experiencing a notable surge. Acute myocardial infarction remains the predominant etiology of cardiogenic shock, followed by heart failure. Recent findings from the DanGer Shock trial indicate that the percutaneous micro-axial flow pump support, in conjunction with standard care, significantly reduced 6-month mortality in patients with acute myocardial infarction-related cardiogenic shock compared to those receiving standard care alone. However, real-world registry data reveal that the 30-day mortality among patients with acute myocardial infarction-related cardiogenic shock, who received concomitant veno-arterial extracorporeal membrane oxygenation support along with micro-axial flow pump, remain suboptimal. The persistent challenge in the field is how to incorporate, escalate, and de-escalate these temporary MCS to further improve clinical outcomes in such clinical scenarios. This review aims to elucidate the current practices surrounding the escalation and de-escalation of temporary MCS in real-world clinical settings and proposes considerations for future advancements in this critical area.</p>","PeriodicalId":15177,"journal":{"name":"Journal of Artificial Organs","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2024-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142154162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Despite the range of body sizes in children, few ventricular assist devices (VAD) exist to support pediatric patients with end-stage heart failure. Large registry data identified weight < 20 kg to be associated with higher rates of VAD-related stroke, compared to > 40 kg. Moreover, patients < 1 years of age experience the highest post-implant mortality, with 1-year survival improving in an age-dependent manner. Within different VAD types, intracorporeal continuous (IC) devices confer the greatest clinical benefit and quality of life compared to paracorporeal alternatives. The major limitation of IC VADs is the technical challenge of implantation into patients of small body size, thus the majority of patients with IC devices are pre-adolescents or older. However, since 2021, the use of HeartMate 3™ (HM3) has expanded to patients as small as 17.7 kg. Although HM3 offers equally favorable survival outcomes irrespective of body size, patients of low body surface area are more likely to experience non-device-related major infections and renal dysfunction, with suggestion for elevated risk of major bleeding and stroke. Innovative imaging strategies have emerged to assess the feasibility of HM3 implantation and facilitate preoperative planning in small children. Moreover, the unmet need for an IC device in the infant population has revived interest in the axial pump, with a pivotal clinical trial currently underway. VAD outcomes in the pediatric population are not equivalent across all ages and body sizes, thus size-stratified analyses and device development to serve the full spectrum of body habitus are key considerations as this field rapidly evolves.
{"title":"Durable left ventricular assist devices in pediatrics: impact of body size on outcomes and size limitations.","authors":"Mimi Xiaoming Deng, Nao Yoshida, Christoph Haller, Aamir Jeewa, Shi-Joon Yoo, Osami Honjo","doi":"10.1007/s10047-024-01467-7","DOIUrl":"https://doi.org/10.1007/s10047-024-01467-7","url":null,"abstract":"<p><p>Despite the range of body sizes in children, few ventricular assist devices (VAD) exist to support pediatric patients with end-stage heart failure. Large registry data identified weight < 20 kg to be associated with higher rates of VAD-related stroke, compared to > 40 kg. Moreover, patients < 1 years of age experience the highest post-implant mortality, with 1-year survival improving in an age-dependent manner. Within different VAD types, intracorporeal continuous (IC) devices confer the greatest clinical benefit and quality of life compared to paracorporeal alternatives. The major limitation of IC VADs is the technical challenge of implantation into patients of small body size, thus the majority of patients with IC devices are pre-adolescents or older. However, since 2021, the use of HeartMate 3™ (HM3) has expanded to patients as small as 17.7 kg. Although HM3 offers equally favorable survival outcomes irrespective of body size, patients of low body surface area are more likely to experience non-device-related major infections and renal dysfunction, with suggestion for elevated risk of major bleeding and stroke. Innovative imaging strategies have emerged to assess the feasibility of HM3 implantation and facilitate preoperative planning in small children. Moreover, the unmet need for an IC device in the infant population has revived interest in the axial pump, with a pivotal clinical trial currently underway. VAD outcomes in the pediatric population are not equivalent across all ages and body sizes, thus size-stratified analyses and device development to serve the full spectrum of body habitus are key considerations as this field rapidly evolves.</p>","PeriodicalId":15177,"journal":{"name":"Journal of Artificial Organs","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2024-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142140199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A 72-year-old female with type 1 diabetes, a history of interstitial pneumonia, and diabetic ketoacidosis was admitted to our hospital with dysphagia. Endoscopy revealed a circumferential neoplastic lesion in the upper to middle esophagus, and a biopsy revealed squamous cell carcinoma. Computed tomography revealed invasion of the left main bronchus, and induction chemotherapy was initiated with a diagnosis of unresectable locally advanced esophageal cancer. After one course of induction chemotherapy, the tumor size reduced, bronchial invasion improved, and thoracoscopic esophagectomy was performed. During surgery and until 3 days after surgery, the patient's blood glucose level was controlled using an artificial pancreas, and the target blood glucose range was set at 140-180 mg/dL. On the fourth postoperative day, the patient was managed using a sliding scale. Mean blood glucose was 186.7 ± 70.0 mg/dL for 3 days before surgery, 190.5 ± 25.0 mg/dL during artificial pancreas therapy from the surgery to the next day, 169.8 ± 22.0 mg/dL during artificial pancreas therapy on the second to third postoperative days, and 174.5 ± 25.0 mg/dL during sliding scale therapy for 4-15 days after surgery. No hypoglycemia or ketoacidosis was noted.
{"title":"A case of perioperative artificial pancreas therapy for a patient with esophageal cancer with type 1 diabetes.","authors":"Hiroyuki Kitagawa, Keiichiro Yokota, Tsutomu Namikawa, Hiromichi Maeda, Michiya Kobayashi, Satoru Seo","doi":"10.1007/s10047-023-01423-x","DOIUrl":"10.1007/s10047-023-01423-x","url":null,"abstract":"<p><p>A 72-year-old female with type 1 diabetes, a history of interstitial pneumonia, and diabetic ketoacidosis was admitted to our hospital with dysphagia. Endoscopy revealed a circumferential neoplastic lesion in the upper to middle esophagus, and a biopsy revealed squamous cell carcinoma. Computed tomography revealed invasion of the left main bronchus, and induction chemotherapy was initiated with a diagnosis of unresectable locally advanced esophageal cancer. After one course of induction chemotherapy, the tumor size reduced, bronchial invasion improved, and thoracoscopic esophagectomy was performed. During surgery and until 3 days after surgery, the patient's blood glucose level was controlled using an artificial pancreas, and the target blood glucose range was set at 140-180 mg/dL. On the fourth postoperative day, the patient was managed using a sliding scale. Mean blood glucose was 186.7 ± 70.0 mg/dL for 3 days before surgery, 190.5 ± 25.0 mg/dL during artificial pancreas therapy from the surgery to the next day, 169.8 ± 22.0 mg/dL during artificial pancreas therapy on the second to third postoperative days, and 174.5 ± 25.0 mg/dL during sliding scale therapy for 4-15 days after surgery. No hypoglycemia or ketoacidosis was noted.</p>","PeriodicalId":15177,"journal":{"name":"Journal of Artificial Organs","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138451567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Purpose: We developed a method to measure the extracellular and intracellular fluid volumes using the kinetics of uric acid in the bodies of Japanese patients undergoing dialysis. In this research, we aimed to assess the prognosis of vascular events using this uric acid kinetic model method.
Methods: We conducted a retrospective cohort study of 1,298 patients who were undergoing hemodialysis or predilution online hemodiafiltration at the end of December 2019 at 13 institutions in Japan. Information on vascular events was acquired in 2020. Vascular event prognosis was defined as the new incidence of one or more of the following four types of vascular events: myocardial infarction, cerebral infarction, cerebral hemorrhage, or limb amputation. We measured the extracellular fluid volume and intracellular fluid volume after dialysis using the uric acid kinetic model method and determined the association between ECV, ICV, and vascular event risk.
Results: A high extracellular volume was substantially linked to an increased risk of vascular events. In addition, while a crude analysis revealed that a high intracellular volume was associated with a low risk of vascular events, this was not statistically significant after multifactorial adjustment. This result was partly affected by the low measurement accuracy of the serum urea nitrogen level used for the intracellular volume calculation.
Conclusions: Extracellular volume calculated using the uric acid kinetic model method is a prognostic factor for vascular events in patients undergoing hemodialysis.
{"title":"Body fluid volume calculated using the uric acid kinetic model relates to the vascular event.","authors":"Shigeru Nakai, Takahito Ito, Kazuhiko Shibata, Kiyoshi Ozawa, Teppei Matsuoka, Kanenori Maeda, Yasushi Ohashi, Takayuki Hamano, Norio Hanafusa, Takahiro Shinzato, Susumu Ookawara, Ikuto Masakane","doi":"10.1007/s10047-023-01421-z","DOIUrl":"10.1007/s10047-023-01421-z","url":null,"abstract":"<p><strong>Purpose: </strong>We developed a method to measure the extracellular and intracellular fluid volumes using the kinetics of uric acid in the bodies of Japanese patients undergoing dialysis. In this research, we aimed to assess the prognosis of vascular events using this uric acid kinetic model method.</p><p><strong>Methods: </strong>We conducted a retrospective cohort study of 1,298 patients who were undergoing hemodialysis or predilution online hemodiafiltration at the end of December 2019 at 13 institutions in Japan. Information on vascular events was acquired in 2020. Vascular event prognosis was defined as the new incidence of one or more of the following four types of vascular events: myocardial infarction, cerebral infarction, cerebral hemorrhage, or limb amputation. We measured the extracellular fluid volume and intracellular fluid volume after dialysis using the uric acid kinetic model method and determined the association between ECV, ICV, and vascular event risk.</p><p><strong>Results: </strong>A high extracellular volume was substantially linked to an increased risk of vascular events. In addition, while a crude analysis revealed that a high intracellular volume was associated with a low risk of vascular events, this was not statistically significant after multifactorial adjustment. This result was partly affected by the low measurement accuracy of the serum urea nitrogen level used for the intracellular volume calculation.</p><p><strong>Conclusions: </strong>Extracellular volume calculated using the uric acid kinetic model method is a prognostic factor for vascular events in patients undergoing hemodialysis.</p>","PeriodicalId":15177,"journal":{"name":"Journal of Artificial Organs","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138798194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-01Epub Date: 2023-12-28DOI: 10.1007/s10047-023-01422-y
Ming Jiang, Wataru Hijikata
High-efficiency plasma skimming is hopeful to prevent hemolysis inside spiral groove bearings (SGBs) because it can exclude red blood cells from the ridge gap with a high shear force. However, no study reveals the shape design of SGBs to improve plasma skimming. Therefore, this study proposed and applied a groove design strategy to designing an optimal SGB for enhancing plasma skimming in a rotary blood pump (RBP). Initially, we proposed the design strategy that the shape of the groove for enhancing plasma skimming corresponds to the direction of blood flow in the ridge gap. Second, we visualized the cell flow in a specially designed experimental RBP to determine the direction of blood flow, which was helpful in the subsequent SGB design. Then, we created an SGB to provide superior plasma skimming and applied it to the experimental RBP. We evaluated the plasma skimming effect of SGB at rotational speeds ranging from 2400 to 3000 rpm and hematocrit conditions between 1% and 40%. At a 1% hematocrit, the plasma skimming efficiency for the entire SGB was greater than 95%. In all hematocrit conditions, the efficiency at the inner ridges of the SGB was greater than 80%. The results showed the designed SGB successfully induced excellent plasma skimming within ridge gaps. This study is the first to propose and apply a shape design strategy to generate excellent plasma skimming within an SGB. This study may contribute to the prevention of SGB hemolysis inside SGB for use in RBPs.
{"title":"Spiral groove bearing design for improving plasma skimming in rotary blood pumps.","authors":"Ming Jiang, Wataru Hijikata","doi":"10.1007/s10047-023-01422-y","DOIUrl":"10.1007/s10047-023-01422-y","url":null,"abstract":"<p><p>High-efficiency plasma skimming is hopeful to prevent hemolysis inside spiral groove bearings (SGBs) because it can exclude red blood cells from the ridge gap with a high shear force. However, no study reveals the shape design of SGBs to improve plasma skimming. Therefore, this study proposed and applied a groove design strategy to designing an optimal SGB for enhancing plasma skimming in a rotary blood pump (RBP). Initially, we proposed the design strategy that the shape of the groove for enhancing plasma skimming corresponds to the direction of blood flow in the ridge gap. Second, we visualized the cell flow in a specially designed experimental RBP to determine the direction of blood flow, which was helpful in the subsequent SGB design. Then, we created an SGB to provide superior plasma skimming and applied it to the experimental RBP. We evaluated the plasma skimming effect of SGB at rotational speeds ranging from 2400 to 3000 rpm and hematocrit conditions between 1% and 40%. At a 1% hematocrit, the plasma skimming efficiency for the entire SGB was greater than 95%. In all hematocrit conditions, the efficiency at the inner ridges of the SGB was greater than 80%. The results showed the designed SGB successfully induced excellent plasma skimming within ridge gaps. This study is the first to propose and apply a shape design strategy to generate excellent plasma skimming within an SGB. This study may contribute to the prevention of SGB hemolysis inside SGB for use in RBPs.</p>","PeriodicalId":15177,"journal":{"name":"Journal of Artificial Organs","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11345322/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139048764","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}